Picture of Clearside Biomedical, logo

CLSDQ — Clearside Biomedical, News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Clearside Biomedical Inc expected to post a loss of 14 cents a share - Earnings Preview

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 11. 
    * The Alpharetta Georgia-based  company is expected to
report  a
58.5% decrease in revenue to $144 thousand from $347 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Clearside
Biomedical Inc
is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is $6​, above​ its last closing price of $1.11.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.13       -0.13      -0.16     Missed  -27
 Sep. 30 2022  -0.05       -0.03      -0.13     Missed  -282.4
 Jun. 30 2022  -0.13       -0.13      -0.13     Met     1.5​
 Mar. 31 2022  -0.08       -0.08      -0.13     Missed  -58.5
 ​​Dec.        0.12        0.16       0.31      Beat    95.8
 31 2021                                                
 Sep. 30 2021  -0.10       -0.08      -0.08     Met     5.9​
 Jun. 30 2021  -0.13       -0.13      -0.11     Beat    14.3
 Mar. 31 2021  -0.11       -0.10      -0.13     Missed  -32.7
 This summary was machine generated May 9 at 17:57 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Clearside Biomedical,

See all news